PGx Testing Helps Avoid Side Effects. BrightKaire Helps Identify What Works.
Compare how no testing, Pharmacogenomics (“PGx”), and BrightKaire differ in guidingantidepressant treatment decisions.
Find your path
Treatment decisions guided by real brain response—not trial and error.
Patient Reality
- Many patients cycle through medications for years
- Genetic tests may explain side effects—but not whether a treatment will help
- BrightKaire reduces unnecessary suffering by pointing toward treatments more likely towork
For Providers
- Psychiatry has historically relied on proxies
- BrightKaire introduces direct biological response evidence—not guesswork
BrightKaire vs PGx Testing vs No Testing
Dimension
No Testing
PGx Testing
BrightKaire
What’s measured
--
Drug metabolism &tolerance
Neurobiological response
Signal type
--
Indirect proxy
Direct functional response
Data type
--
Static genetic markers
Dynamic cellular behavior
Primary value
Trial-and-error
Avoid side effects
Increase likelihood ofresponse
Clinical question answered
--
“Can they tolerate this?”
“Will this work?”
What Each Approach Actually Enables
Clinical Insight
No Testing
PGx Testing
BrightKaire
Understand metabolism
--
Assess side effect risk
--
Use genetic data
--
Guide beyond trial-and-error
--
Limited
Measure brain response
--
--
Predict likelihood a treatment will work
--
--
The Key Difference
PGx testing helps avoid what might not work. BrightKaire helps identify what is more likely to work.
Move Beyond Trial-and-Error
Start making treatment decisions based on how a patient’s brain actually responds.
See how it works